Code Compliance Committee

Basic Policy

The Code Compliance Committee (hereinafter referred to as "the Committee") shall assist member companies to comply not only with relevant laws and regulations but also with the JPMA Code of Practice and other voluntary codes, and to fulfill their social responsibilities with high ethical standards as members of life-related industries.

Priority Issues

  1. Supporting Compliance Promotion of Member Companies
  2. Promotion of appropriate information disclosure based on Transparency Guideline
  3. Compliance with the "Guidelines for Activities Related to Provision of Marketing Information on Ethical Drugs
  4. Collaboration, collection, dissemination of information, and feedback with the government and related domestic and international organizations such as the Federation of Pharmaceutical Manufacturers and Associations of Japan (JPMA), Japan Fair Trade Council for Marketing of Ethical Drugs (JFTC), and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Priority Tasks to be addressed

1. Support member companies in promoting compliance

  1. Support member companies in promoting compliance by conducting compliance surveys, etc., as necessary, identifying issues and considering countermeasures, holding regular training sessions, etc. (Code/Compliance Managers and Practice Managers Meetings, etc.), implementing measures during the JPMA Code Awareness Promotion Month, and sending out notices as necessary. Support member companies in promoting compliance by holding regular training sessions, etc. (Code/Compliance Manager meetings, etc.), implementing measures during the Pharmaceutical Association of Japan (PAK) Code Awareness Month, and sending notices as necessary.
  2. Respond promptly and appropriately to inquiries, complaints, etc. concerning the JPMA Code of Practice, and if necessary, take measures to request voluntary improvements from member companies that have violated the Code, and share examples of such measures with member companies to prevent recurrence.

2. Promote appropriate information disclosure based on the Transparency Guideline

  1. Support activities to increase the transparency of the relationship between member companies and medical institutions, and promote information disclosure in accordance with the Transparency Guideline.
  2. Support appropriate information disclosure by member companies by taking necessary measures such as holding training sessions (Transparency Guideline contact person meetings) and updating FAQs to further deepen member companies' understanding of the Transparency Guideline.

3. Respond to the "Guidelines for Activities to Provide Information on the Sale of Ethical Drugs

  1. As the committee in charge of guidelines for sales information provision activities for ethical drugs, the committee supports member companies' compliance with the guidelines with advice from the Advisory Council.
  2. After confirming and reviewing the inappropriate cases in the Survey Project on Activities to Provide Sales Information (a project commissioned by the Monitoring, Guidance and Countermeasures for Drugs Division, Pharmaceutical Affairs Bureau, Ministry of Health, Labour and Welfare), issue notices, etc. as necessary and ensure member companies comply with the guidelines.
  3. Collect information on relevant laws and regulations, administrative notices, etc. in a timely manner and share it with member companies.

4. liaise with the government and related domestic and international organizations such as the Japan Pharmaceutical Manufacturers Association, the Japan Fair Trade Association, IFPMA, etc., collect and disseminate information, and provide feedback

  1. Promote the "Consensus Framework for Ethical Collaboration in Japan" agreed upon and signed in 2018 among member companies and support the dissemination activities of related organizations in Japan in cooperation with the JFMA.
  2. Participate in international compliance promotion activities, including IFPMA Ethics & Business Integrity Committee meetings and APEC Business Ethics for SMEs Forum 2026, to gather international trends in the pharmaceutical industry and disseminate Japanese ideas. The results obtained through these promotion activities will be fed back to the Committee and reflected in its initiatives as necessary. 4.
  3. Collect information on relevant laws and regulations, administrative notices, etc. in a timely manner and share it with member companies.

Other Activity Plans

Establish subcommittees and task forces as necessary to enhance committee activities and to collaborate with related committees.

Related Information

Share this page

TOP

Site Search